SCYXSCYNEXIS, Inc.

1. Sep 28, 2026On September 25, 2026, SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) entered into an Award/Contract (the “BARDA Contract”) with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human …Material agreement entered · Form 8-K
2. Sep 22, 2026On September 18, 2026, the Board of Directors (the “Board”) of SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) appointed Steven K. Burke, M.D., as a member of the Board, effective September 18, 2026.Director or officer change · Form 8-K
3. Sep 10, 2026Departure of Chief Financial Officer On September 9, 2026, the then-current Chief Financial Officer of SCYNEXIS, Inc. (the “Company” or “SCYNEXIS”), Ivor Macleod, CPA, MBA, notified the Company of his intent to retire.Director or officer change · Form 8-K
4. Jun 26, 2026The Company has filed with the Commission a Registration Statement on Form S-3 (Registration Statement No. 333-295493) (the “Registration Statement”), which was declared effective by the Commission as of May 8, 2026, for the purpose of registering under the Securities Act of 1933, as amended (the “Securities Act”) …Charter/bylaw amendment or fiscal-year change · Form 8-K
5. May 29, 2026On May 28, 2026, SCYNEXIS, Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”), to effect a one-for-eight (1:8) reverse stock split of its outstanding …Charter/bylaw amendment or fiscal-year change · Form 8-K
6. May 22, 2026On May 19, 2026, the Board of Directors of the Company approved the filing with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”), to effect a one-for-eight (1:8) reverse stock split of its common stock …Shareholder vote results · Form 8-K
7. Apr 20, 2026On April 16, 2026, Steven C. Gilman, a member of the Board of Directors (the “Board”) of SCYNEXIS, Inc. (the “Company”), notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”)Director or officer change · Form 8-K
8. Mar 31, 2026Corporate Deck March 2026.Regulation FD disclosure · press release
9. Mar 31, 2026Private Placement On March 30, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain new and existing institutional and accredited investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to …Material agreement entered · Form 8-K
10. Mar 31, 2026Asset Purchase Agreement On March 30, 2026, SCYNEXIS, Inc. (the “Company”) and Poxel SA, a French corporation (“Poxel”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) pursuant to which the Company (i) acquired all of Poxel’s right, title and interest in Poxel’s direct AMP kinase activator …Material agreement entered · Form 8-K
11. Oct 15, 2025Binding Memorandum of Understanding for Amendment to Exclusive License Agreement with GSK On October 14, 2025, SCYNEXIS, Inc. (“SCYNEXIS”) and GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) entered into a binding memorandum of understanding (the “Binding 2025 MOU”) for amendment to the exclusive license …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.